David Meeker, CEO of Rhythm Pharmaceuticals, previously led Sanofi Genzyme and has been a key player in rare disease biotech. He shares his journey from physician to biotech leader, highlighting breakthroughs like enzyme replacement therapies for Gaucher disease. David emphasizes the importance of patient-centric approaches, the challenges of developing therapies for rare diseases, and the evolving dynamics between biotech and big pharma. He discusses regulatory impacts and the necessity for a clear focus in addressing unmet medical needs in the industry.